First Tracks Biotherapeutics Inc. – Filings and Transcripts

NASDAQ: TRAX
Share price (9/18/26): $38.60
Market cap (9/18/26): $1.379 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

Prospectuses and Registrations Filter

Prospectus supplement

Prospectus supplement

Prospectus supplement

Initial registration of new securities

Draft registration statement

Ownership Filter

Ware J. Anthony

Ware J. Anthony

News Filter

Announces Second Quarter 2026 Financial Results and Provides Business Update

Material Definitive Agreement

Announces First Quarter 2026 Financial Results and Provides Business Update

Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

• Advance Next-Generation Antibody Therapies That Modulate Immune Pathways Implicated in Autoimmune and Inflammatory Diseases, Including ANB033, Rosnilimab and ANB101 • Launch With ~$180 Million in Cash and a Two-Year Cash Runway

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

SEC STAFF ACTION